3.40Open3.40Pre Close0 Volume200 Open Interest195.00Strike Price0.00Turnover9183.21%IV22.20%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry3.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1179Delta0.0037Gamma72.43Leverage Ratio-2578.6081Theta0.0000Rho-8.54Eff Leverage0.0011Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet